Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....
Opioid-Induced Constipation Treatment Market: By Drug Type, By Formulation Type, By Administration, By Distribution Channel and Region Forecast 2019-2030
Opioid Induced Constipation Treatment Market size was valued at US$ 2911.97 million in 2023 and is poised to grow at a CAGR of 4.7% from 2024-2030. Global market are the drugs used for its pain relieving properties in non-cancer and chronic kidney diease (ckd) drugs pain. The adverse effects associated with the opioids are decreasing gastrointestinal tracts motility, making patients strain, and making of solid discharges.
Furthermore, long-term use of opioids cause harm to the sensory system, limits the release of endogenous opioids such as endorphins. Adults are most likely to prone to opioid-induced constipation owing to less immobility, poor diet, and fluid intake. The symptoms associated with the opioid-induced constipation are included dry and hard tools, leathery feeling, painful defecation, bulged abdomen, and loss of appetite. The market growing at a significant CAGR due to rise in the aging population using opioid analgesics for chronic pains. Increase in the illicit use of medications, prolonged usage of opioids in the treatment of pain, an increase in the prevalence of cancer is anticipated to boost the global Opioid-Induced Constipation Treatment Market.
Furthermore, launching of newer drugs, growing FDA approvals, positive outcomes in clinical trials, and rise in the healthcare expenditure are expected to propel the market over the forecast period. However, lack of awareness regarding opioid induced constipation in patients, the absence of treatment innovations, a high cost of newer pharmaceuticals, adverse effects, including nausea, a risk of heart problems and strokes associated with these drugs and unfavorable reimbursement policies expected to hamper the growth of the market.
This report studies global market dynamics elaborately to identify the current trends & drivers, future opportunities and possible challenges to the key stakeholders operating in the market. In addition, The global market report includes human demographics; regulatory scenario, and competition analysis with vividly illustrated the competition dashboard to assess the market competition. Moreover, PBI analyzed global market to better equip clients with possible investment opportunities across the regions (regional Investment Hot-Spots) and market unmet needs (Product opportunities).
Study Period
2024-2030Base Year
2023CAGR
4.7%Largest Market
North-AmericaFastest Growing Market
Asia Pacific
Opioid-induced constipation is becoming increasingly common. In 2013, the American Academy of Pain Medicine (AAPM) estimated that about 100 million individuals in the United States experienced opioid-induced constipation. Furthermore, the AAPM predicted that the number of instances would increase as the number of people using opioids increased. There is a rising awareness of the availability of a wide range of opioid medications. Patients will be more likely to use these medications to treat chronic pain as a result of this. The growing number of people suffering from opioid-induced constipation, particularly in North America, is expected to propel the total opioid-induced constipation treatment business forward. Because of the enormous number of persons who take opioid medicines, the regional market is expected to increase at a significant rate. This is due to the high prevalence of chronic pain-related diseases in this area.
Report Benchmarks |
Details |
Report Study Period |
2024-2030 |
Market Size in 2023 |
US$ 2911.97 million |
Market CAGR |
4.7% |
By Drug Type |
|
By Formulation Type |
|
By Distribution Channel |
|
By Region |
|
Download Free Sample Report
The opioid-induced constipation treatment market size is valued at US$ 2911.97 million in 2023 and is poised to grow at a CAGR of 4.7% from 2024-2030.
Rise in the Availability of Effective OIC Drugs Along with Growing Prevalence of Chronic Idiopathic Pains
Europe is the fastest-growing for the market
1.Executive Summary |
2.Global Opioid Induced Constipation Treatment Market Introduction |
2.1.Global Opioid Induced Constipation Treatment Market - Taxonomy |
2.2.Global Opioid Induced Constipation Treatment Market - Definitions |
2.2.1.Drug Type |
2.2.2. Formulation Type |
2.2.3.Distribution Channel |
2.2.4.Region |
3.Global Opioid Induced Constipation Treatment Market Dynamics |
3.1. Drivers |
3.2. Restraints |
3.3. Opportunities/Unmet Needs of the Market |
3.4. Trends |
3.5. Product Landscape |
3.6. New Product Launches |
3.7. Impact of COVID 19 on Market |
4.Global Opioid Induced Constipation Treatment Market Analysis, 2019 - 2023 and Forecast 2024 - 2030 |
4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
4.3. Market Opportunity Analysis |
5.Global Opioid Induced Constipation Treatment Market By Drug Type, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
5.1. Peripherally restricted ?-opioid receptor antagonists |
5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.1.3. Market Opportunity Analysis |
5.2. Non-selective opioid antagonists |
5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.2.3. Market Opportunity Analysis |
5.3. ? -opioid receptor antagonists |
5.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.3.3. Market Opportunity Analysis |
5.4. Locally acting chloride channel activators |
5.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.4.3. Market Opportunity Analysis |
6.Global Opioid Induced Constipation Treatment Market By Formulation Type, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
6.1. Solids |
6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.1.3. Market Opportunity Analysis |
6.2. Semi-solids |
6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.2.3. Market Opportunity Analysis |
6.3. Liquids |
6.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.3.3. Market Opportunity Analysis |
7.Global Opioid Induced Constipation Treatment Market By Distribution Channel, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
7.1. Drugstore |
7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.1.3. Market Opportunity Analysis |
7.2. Retail pharmacies |
7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.2.3. Market Opportunity Analysis |
7.3. Hospital pharmacies |
7.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.3.3. Market Opportunity Analysis |
8.Global Opioid Induced Constipation Treatment Market By Region, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
8.1. North America |
8.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.1.3. Market Opportunity Analysis |
8.2. Europe |
8.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.2.3. Market Opportunity Analysis |
8.3. Asia Pacific (APAC) |
8.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.3.3. Market Opportunity Analysis |
8.4. Middle East and Africa (MEA) |
8.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.4.3. Market Opportunity Analysis |
8.5. Latin America |
8.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
8.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.5.3. Market Opportunity Analysis |
9.North America Opioid Induced Constipation Treatment Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
9.1. Drug Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.1.1.Peripherally restricted ?-opioid receptor antagonists |
9.1.2.Non-selective opioid antagonists |
9.1.3.? -opioid receptor antagonists |
9.1.4.Locally acting chloride channel activators |
9.2. Formulation Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.2.1.Solids |
9.2.2.Semi-solids |
9.2.3.Liquids |
9.3. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.3.1.Drugstore |
9.3.2.Retail pharmacies |
9.3.3.Hospital pharmacies |
9.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.4.1.United States of America (USA) |
9.4.2.Canada |
10.Europe Opioid Induced Constipation Treatment Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
10.1. Drug Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.1.1.Peripherally restricted ?-opioid receptor antagonists |
10.1.2.Non-selective opioid antagonists |
10.1.3.? -opioid receptor antagonists |
10.1.4.Locally acting chloride channel activators |
10.2. Formulation Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.2.1.Solids |
10.2.2.Semi-solids |
10.2.3.Liquids |
10.3. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.3.1.Drugstore |
10.3.2.Retail pharmacies |
10.3.3.Hospital pharmacies |
10.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.4.1.Germany |
10.4.2.France |
10.4.3.Italy |
10.4.4.United Kingdom (UK) |
10.4.5.Spain |
11.Asia Pacific (APAC) Opioid Induced Constipation Treatment Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
11.1. Drug Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.1.1.Peripherally restricted ?-opioid receptor antagonists |
11.1.2.Non-selective opioid antagonists |
11.1.3.? -opioid receptor antagonists |
11.1.4.Locally acting chloride channel activators |
11.2. Formulation Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.2.1.Solids |
11.2.2.Semi-solids |
11.2.3.Liquids |
11.3. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.3.1.Drugstore |
11.3.2.Retail pharmacies |
11.3.3.Hospital pharmacies |
11.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.4.1.China |
11.4.2.India |
11.4.3.Australia and New Zealand (ANZ) |
11.4.4.Japan |
11.4.5.Rest of APAC |
12.Middle East and Africa (MEA) Opioid Induced Constipation Treatment Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
12.1. Drug Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.1.1.Peripherally restricted ?-opioid receptor antagonists |
12.1.2.Non-selective opioid antagonists |
12.1.3.? -opioid receptor antagonists |
12.1.4.Locally acting chloride channel activators |
12.2. Formulation Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.2.1.Solids |
12.2.2.Semi-solids |
12.2.3.Liquids |
12.3. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.3.1.Drugstore |
12.3.2.Retail pharmacies |
12.3.3.Hospital pharmacies |
12.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.4.1.GCC Countries |
12.4.2.South Africa |
12.4.3.Rest of MEA |
13.Latin America Opioid Induced Constipation Treatment Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
13.1. Drug Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.1.1.Peripherally restricted ?-opioid receptor antagonists |
13.1.2.Non-selective opioid antagonists |
13.1.3.? -opioid receptor antagonists |
13.1.4.Locally acting chloride channel activators |
13.2. Formulation Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.2.1.Solids |
13.2.2.Semi-solids |
13.2.3.Liquids |
13.3. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.3.1.Drugstore |
13.3.2.Retail pharmacies |
13.3.3.Hospital pharmacies |
13.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.4.1.Brazil |
13.4.2.Mexico |
13.4.3.Rest of LA |
14. Competition Landscape |
14.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
14.2.1.GlaxoSmithKline plc (U.K.) |
14.2.2.AstraZeneca U.K) |
14.2.3.Pfizer Inc. (U.S.) |
14.2.4.SLA Pharma AG (U.K.) |
14.2.5.AIKO Biotechnology, Inc. (U.S.) |
14.2.6.Cubist Pharmaceuticals (Merck & Co. Inc.,) (U.S.) |
14.2.7.Takeda Pharmaceutical Company Limited (Japan) |
14.2.8.Boehringer Ingelheim GmbH (Germany) |
14.2.9.Bayer AG (Germany) |
14.2.10.Valeant (Canada) |
14.2.11.Abbott Laboratories (U.S.) |
14.2.12.Purdue Pharma LP (U.S.) |
14.2.13.Shionogi Inc. (U.S.) |
14.2.14.Cosmo Pharmaceuticals N.V. (Ireland) |
15. Research Methodology |
16. Appendix and Abbreviations |
Key Market Players